H.C. Wainwright analyst Patrick Trucchio initiated coverage of Alto Neuroscience (ANRO) with a Buy rating and $10 price target Alto is redefining neuropsychiatric drug development through the application of precision medicine in psychiatry, a “paradigm-shifting approach” that targets biomarker-defined patient populations, the analyst tells investors in a research note. The firm believes the company’s “differentiated” Precision Psychiatry Platform has the potential to optimize patient-treatment matching and outcomes in central nervous system disorders.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANRO:
- Buy Rating Reaffirmed for Alto Neuroscience, Inc. Amid Promising Pipeline and Upcoming Data Readouts
- Promising Clinical Trials and Strong Financials Justify Buy Rating for Alto Neuroscience, Inc.
- Alto Neuroscience Advances Clinical Trials with Strong Financials
- Alto Neuroscience Announces Board Member Departures
- Alto Neuroscience, Inc. (ANRO) Q4 Earnings Cheat Sheet